<DOC>
	<DOCNO>NCT00000747</DOCNO>
	<brief_summary>Primary : To evaluate rate development resistance nevirapine HIV-1 infected individual . To evaluate safety nevirapine HIV-1 infected individual CD4 count great equal 500 cells/mm3 . Secondary : To evaluate effect nevirapine surrogate marker . The anti-HIV agent nevirapine associate rapid emergence resistance administer alone combination zidovudine HIV-infected patient CD4 count &lt; = 400 cells/mm3 . In person less advanced HIV disease less viral burden , emergence resistance may delay , thus permit evaluation beneficial effect population currently establish therapy .</brief_summary>
	<brief_title>An Open-Label , Pilot Study Evaluate Development Resistance Nevirapine ( BI-RG-587 ) HIV-Infected Patients With CD4 Cell Count &gt; = 500/mm3</brief_title>
	<detailed_description>The anti-HIV agent nevirapine associate rapid emergence resistance administer alone combination zidovudine HIV-infected patient CD4 count &lt; = 400 cells/mm3 . In person less advanced HIV disease less viral burden , emergence resistance may delay , thus permit evaluation beneficial effect population currently establish therapy . Ten patient receive nevirapine daily 12 week . After 12 week therapy , patient resistance evident week 4 adequate safety profile continue receive nevirapine additional 12 week . Clinical immunological assessment perform week 4 , 8 , 12 , 16 , 20 , 24 . Virological assessment perform week 24 . If 50 percent patient develop resistance time , study discontinue .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Positive serum antibody HIV1 ELISA Western blot . CD4 count &gt; = 500 cells/mm3 within 2 month prior study entry , two additional count average &gt; = 450 cells/mm3 baseline study day 0 ( take least 48 hour apart ) . No AIDSdefining disease . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : More four loose stool per day . Participation experimental trial include vaccine trial . Concurrent Medication : Excluded : Other approve investigational antiretroviral agent , investigational agent , vaccine . Glucocorticoids steroid hormone . Dicumarol , warfarin , anticoagulant . Digitoxin . Valproic acid . Tolbutamide . Doxycycline . Chloramphenicol . Phenobarbital barbiturates . Excluded 4 hour nevirapine dose : Antacids ( particularly contain calcium carbonate ) . H2 blocker , carafate , cholestyramine resin , alcohol alcoholcontaining substance , benzodiazepine ( e.g. , diazepam , triazolam ) . Patients follow prior condition exclude : History clinically important disease HIV infection . Prior Medication : Excluded within 1 month prior study entry : Any immunosuppressive , immunomodulatory , cytotoxic treatment . Use drug alcohol sufficient impair compliance protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Drug Resistance</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Nevirapine</keyword>
</DOC>